Cargando…
P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429307/ http://dx.doi.org/10.1097/01.HS9.0000846756.44372.25 |
| _version_ | 1784779400145797120 |
|---|---|
| author | Weisel, K. Chari, A. Usmani, S. Z. Goldschmidt, H. Mateos, M.-V. Qi, K. Londhe, A. Nair, S. Lin, X. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Moreau, P. |
| author_facet | Weisel, K. Chari, A. Usmani, S. Z. Goldschmidt, H. Mateos, M.-V. Qi, K. Londhe, A. Nair, S. Lin, X. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Moreau, P. |
| author_sort | Weisel, K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429307 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94293072022-08-31 P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS Weisel, K. Chari, A. Usmani, S. Z. Goldschmidt, H. Mateos, M.-V. Qi, K. Londhe, A. Nair, S. Lin, X. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Moreau, P. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429307/ http://dx.doi.org/10.1097/01.HS9.0000846756.44372.25 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Weisel, K. Chari, A. Usmani, S. Z. Goldschmidt, H. Mateos, M.-V. Qi, K. Londhe, A. Nair, S. Lin, X. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Moreau, P. P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title | P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title_full | P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title_fullStr | P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title_full_unstemmed | P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title_short | P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS |
| title_sort | p972: indirect comparison of teclistimab in majestec-1 versus physician’s choice of therapy in long-term follow-up of triple-class exposed relapsed/refractory multiple myeloma in daratumumab trials |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429307/ http://dx.doi.org/10.1097/01.HS9.0000846756.44372.25 |
| work_keys_str_mv | AT weiselk p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT charia p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT usmanisz p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT goldschmidth p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT mateosmv p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT qik p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT londhea p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT nairs p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT linx p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT peil p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT ammanne p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT kobosr p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT smitj p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT parekht p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT slavcevm p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials AT moreaup p972indirectcomparisonofteclistimabinmajestec1versusphysicianschoiceoftherapyinlongtermfollowupoftripleclassexposedrelapsedrefractorymultiplemyelomaindaratumumabtrials |